Slides on Key Decisions in HIV Care: Optimizing Switch Strategies for Patients With Viral Suppression

Learn key considerations when selecting a new ART regimen for patients with viral suppression who need a change in HIV treatment. Topics include weighing the pros and cons of switching to contemporary 3-drug therapy regimens, oral 2-drug options, and long-acting injectable 2-drug regimens.
Daniel R. Kuritzkes, MD
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 908 KB
Released: June 7, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

REACH study: adherence to dapivirine vaginal ring and oral PrEP among African females 16-21 years, in Clinical Care Options (CCO) report from IAS 2021

Released: July 24, 2021

Dr Joseph Eron and Clinical Care Options (CCO): Weight gain in initial ART, GEMINI, ADVANCE trials, and more

Joseph J. Eron, Jr., MD Released: July 22, 2021

Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue